Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
23 hedge funds and large institutions have $2.81M invested in Statera Biopharma, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 5 closing their positions.
67% more call options, than puts
Call options by funds: $40K | Put options by funds: $24K
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
10% more funds holding
Funds holding: 21 → 23 (+2)
35% less capital invested
Capital invested by funds: $4.31M → $2.81M (-$1.49M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.25M |
| 2 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$88.3K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$73.8K |
| 4 |
Renaissance Technologies
New York
|
+$61.2K |
| 5 |
DY
Dowling & Yahnke
San Diego,
California
|
+$55.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$127K |
| 2 |
SFA
Sequoia Financial Advisors
Akron,
Ohio
|
-$69K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$43.1K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$20K |
| 5 |
US Bancorp
Minneapolis,
Minnesota
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Bank of America
Charlotte,
North Carolina
| – | -$193 | -51 | -34% |
|
27
Wells Fargo
San Francisco,
California
| – | +$398 | +105 | +206% |
|
STAB Hedge Fund Activity: Q3 2021 in Review
23 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q3 2021, worth a combined $2.81M — down 35% from $4.31M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new STAB positions and 5 closed out — a net gain of 3 holders — while 7 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.25M. The largest seller was Sabby Management, cutting an estimated $127K.
- 23 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q3 2021, up from 21 in Q2 2021.
- Funds reported $2.81M of Statera Biopharma, Inc. Common Stock stock for Q3 2021, down 35% quarter-over-quarter.
- 8 funds opened new Statera Biopharma, Inc. Common Stock positions in Q3 2021 and 5 closed out, a net change of +3 holders.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q3 2021 was Vanguard Group, an estimated $1.25M added.
- The largest Statera Biopharma, Inc. Common Stock seller in Q3 2021 was Sabby Management, an estimated $127K sold.
Based on aggregated 13F filings for Q3 2021.